NeuroDerm (NDRM) Misses Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
NeuroDerm Announces Third Quarter 2015 Financial Results
November 11, 2015 7:02 AM ESTREHOVOT, Israel, Nov. 11, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the third quarter ended September 30, 2015.
"We made solid progress in the third quarter developing our next-generation treatments for Parkinson's disease through subcutaneous administration of the first ever liquid formulation of levodopa/carbidopa to provide a better quality of life for patients suffering from this debilitating disease," said Oded Lieberman, PhD, CEO of NeuroDerm. "We look forward to executing on our streamlined clinical development program... More
NeuroDerm Announces Third Quarter 2015 Financial Results
November 11, 2015 7:02 AM ESTREHOVOT, Israel, Nov. 11, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the third quarter ended September 30, 2015.
"We made solid progress in the third quarter developing our next-generation treatments for Parkinson's disease through subcutaneous administration of the first ever liquid formulation of levodopa/carbidopa to provide a better quality of life for patients suffering from this debilitating disease," said Oded Lieberman, PhD, CEO of NeuroDerm. "We look forward to executing on our streamlined clinical development program... More
NeuroDerm Announces Streamlined U.S. Development Plan Following FDA Feedback on ND0612H and ND0612L for the Treatment of Parkinson's Disease
November 11, 2015 7:00 AM ESTBased on FDA input, NeuroDerm is not required to conduct its largest Phase III pivotal trial of 360 patients
Company to host conference call today at 8:30 a.m. ET
REHOVOT, Israel, Nov. 11, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq: NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has modified its U.S. development plan for ND0612H and ND0612L, the company's continuous, subcutaneously delivered levodopa/carbidopa product candidates for the treatment of Parkinson's... More
NeuroDerm Announces Streamlined U.S. Development Plan Following FDA Feedback on ND0612H and ND0612L for the Treatment of Parkinson's Disease
November 11, 2015 7:00 AM ESTBased on FDA input, NeuroDerm is not required to conduct its largest Phase III pivotal trial of 360 patients
Company to host conference call today at 8:30 a.m. ET
REHOVOT, Israel, Nov. 11, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq: NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has modified its U.S. development plan for ND0612H and ND0612L, the company's continuous, subcutaneously delivered levodopa/carbidopa product candidates for the treatment of Parkinson's... More
